Recent Quotes (30 days)

You have no recent quotes
chg | %

Medifocus Inc.  

(Public, CVE:MFS)   Watch this stock  
Find more results for MFS
0.0400
0.0000 (0.00%)
Delayed:   9:30AM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.04 - 0.04
52 week 0.04 - 0.22
Open 0.04
Vol / Avg. 30,000.00/64,098.00
Mkt cap 5.11M
P/E     -
Div/yield     -
EPS -0.06
Shares 127.54M
Beta     -
Inst. own     -
Mar 24, 2015
Q3 2014 Medifocus Inc Earnings Release
  

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -121.34% -113.94%
Operating margin -120.20% -97.00%
EBITD margin - -83.09%
Return on average assets -89.43% -91.09%
Return on average equity - -340.93%
CDP Score - -

Address

The Exchange Tower Suite 1800, 130 King Street West, PO Box 427
BURLINGTON, ON M5X 1E3
Canada
+1-905-3197070 (Phone)
+1-905-5176060 (Fax)

Website links

Description

Medifocus Inc. is a Canada-based company that develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia (BPH). The Company owns two technology platforms with comprehensive United States and international patent protection: The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The platform can potentially be used to treat cancers in prostate, rectum, cervix and esophagus. The Adaptive Phased Array (APA) Microwave Focusing Platform directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company�s APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, is in pivotal Phase-III clinical trials.

Officers and directors

Grant B. Walsh Chairman of the Board
Yim-Pan Cheung Ph.D. President, Chief Executive Officer, Director
Mirsad Jakubovic Chief Financial Officer
John Mon Chief Operating Officer
Shuen Chuen Chan Independent Director
Age: 64
Augustine Pok Yu Chow Ph.D. Independent Director
Tak Cheung Yam Independent Director
Age: 51